DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/gq3r3g/actinic_solar) has announced the addition of the "Actinic (Solar) Keratosis - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Actinic (Solar) Keratosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Actinic (Solar) Keratosis and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- 3M Drug Delivery Systems
- Advancell
- Biofrontera AG
- Clinuvel Pharmaceuticals Limited
- Digna Biotech, S.L.
- Dolorgiet Gmbh & Co. Kg
- Foamix Pharmaceuticals Ltd.
- G&E Herbal Biotechnology Co., Ltd.
- Galderma S.A.
- Kinex Pharmaceuticals, LLC
- LEO Pharma A/S
- Novartis AG
- Novelix Pharmaceuticals, Inc.
- Promius Pharma, LLC
- Spherium Biomed S.L.
Drug Profiles
- 854-A
- ACT-01
- AD-17137
- AK-3012
- aminolevulinic acid hydrochloride
- ANs-40
- ANS-401
- ANS-403
- CUV-9900
- DFD-07
- DFD-08
- disitertide
- imiquimod
- KX-01
- LEO-43204
- LFX-453
- NVX-207
- Recombinant Peptide for Dermatology, Immunology and Oncology
- resiquimod
- Small Molecules to Activate Protein Kinase C for Dermatology and Cancer
- SP-12054
- SRT-100
- sulindac + hydrogen peroxide
- VPE-001
For more information visit http://www.researchandmarkets.com/research/gq3r3g/actinic_solar
